View Future GrowthRoivant Sciences 과거 순이익 실적과거 기준 점검 0/6Roivant Sciences은 연평균 24.5%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 15.2%의 비율로 감소했습니다.핵심 정보24.55%순이익 성장률25.07%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률-15.21%자기자본이익률-7.52%순이익률-3,629.19%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 21Full year 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2026 results: US$0.43 loss per share (improved from US$0.75 loss in FY 2025). Net loss: US$299.8m (loss narrowed 45% from FY 2025). Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) exceeded analyst estimates by 57%. Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings.공시 • May 12Roivant Sciences Ltd. to Report Q4, 2026 Results on May 20, 2026Roivant Sciences Ltd. announced that they will report Q4, 2026 results Pre-Market on May 20, 2026Reported Earnings • Feb 07Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: US$0.38 loss per share (further deteriorated from US$0.22 loss in 3Q 2025). Revenue: US$2.00m (down 78% from 3Q 2025). Net loss: US$265.9m (loss widened 69% from 3Q 2025). Revenue missed analyst estimates by 67%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings.공시 • Jan 24Roivant Sciences Ltd. to Report Q3, 2026 Results on Feb 06, 2026Roivant Sciences Ltd. announced that they will report Q3, 2026 results Pre-Market on Feb 06, 2026Reported Earnings • Nov 12Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2026 results: US$0.17 loss per share (improved from US$0.25 loss in 2Q 2025). Revenue: US$1.57m (down 65% from 2Q 2025). Net loss: US$113.5m (loss narrowed 39% from 2Q 2025). Revenue missed analyst estimates by 75%. Earnings per share (EPS) exceeded analyst estimates by 49%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.공시 • Oct 28Roivant Sciences Ltd. to Report Q2, 2026 Results on Nov 10, 2025Roivant Sciences Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025모든 업데이트 보기Recent updatesRecent Insider Transactions Derivative • 7hPresident & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of May. If the sale is conducted around the recent share price of US$30.27, it would amount to US$6.1m. Since June 2025, Eric's direct individual holding has increased from 1.31m shares to 1.33m. Company insiders have collectively sold US$382m more than they bought, via options and on-market transactions in the last 12 months.Price Target Changed • May 24Price target increased by 8.2% to US$38.63Up from US$35.71, the current price target is an average from 12 analysts. New target price is 29% above last closing price of US$29.96. Stock is up 176% over the past year. The company is forecast to post a net loss per share of US$1.14 next year compared to a net loss per share of US$0.43 last year.속보 • May 22Roivant Sciences Turns Profitable as Brepocitinib Launch and Key Drug Data Await Regulatory DecisionsRoivant Sciences swung to profitability in Q4 FY 2026, reversing an attributable net loss from the prior year, which coincided with a roughly 15% move higher in the stock. The company is targeting a commercial launch of oral autoimmune therapy brepocitinib by the end of September, following FDA acceptance and a target action date in Q3. Roivant reported encouraging preliminary open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis and is advancing a Phase II study of inhaled mosliciguat for pulmonary hypertension associated with interstitial lung disease, with top-line data planned for the second half of 2026. The shift to profitability, alongside advancing late-stage and mid-stage drug programs, highlights how much of the story is tied to successful execution on upcoming regulatory and clinical milestones. Investors following Roivant will likely focus on the brepocitinib launch timeline, future data updates for IMVT-1402 and mosliciguat, and the risks that delays or weaker-than-expected clinical results could have on sentiment.Reported Earnings • May 21Full year 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2026 results: US$0.43 loss per share (improved from US$0.75 loss in FY 2025). Net loss: US$299.8m (loss narrowed 45% from FY 2025). Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) exceeded analyst estimates by 57%. Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings.Seeking Alpha • May 21Roivant: Immunovant's Rheumatoid Arthritis Win Validates The BuySummary Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant’s IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV’s financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability. Risks include late-stage trial failure, competition, regulatory setbacks, pricing pressure, premium valuation, and complexity in valuing the parent across its 'vants.' Read the full article on Seeking Alpha내러티브 업데이트 • May 19ROIV: Settlement Windfall Will Shift Focus Toward 2026 Clinical ReadoutsAnalysts have increased their average price target on Roivant Sciences by about $0.04 to $35.71, citing updated models that factor in litigation settlement proceeds, the brepocitinib priority review and a lower assumed discount rate, along with adjusted profit margin and future P/E assumptions. Analyst Commentary Recent research updates on Roivant Sciences show a mix of optimism around litigation proceeds and key pipeline milestones, alongside some caution around how much of this is already reflected in current valuations.공시 • May 12Roivant Sciences Ltd. to Report Q4, 2026 Results on May 20, 2026Roivant Sciences Ltd. announced that they will report Q4, 2026 results Pre-Market on May 20, 2026Recent Insider Transactions Derivative • Apr 26President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of April. If the sale is conducted around the recent share price of US$29.59, it would amount to US$5.9m. Since June 2025, Eric's direct individual holding has increased from 1.31m shares to 1.33m. Company insiders have collectively sold US$388m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Apr 22CEO & Director recently sold US$8.4m worth of stockOn the 16th of April, Matthew Gline sold around 290k shares on-market at roughly US$29.16 per share. This transaction amounted to 78% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Matthew has been a net seller over the last 12 months, reducing personal holdings by US$8.4m.내러티브 업데이트 • Apr 21ROIV: Settlement Cash Will Shift Focus Toward 2026 Late Stage ReadoutsThe updated analyst price target for Roivant Sciences moves from $33.25 to about $35.67, with analysts pointing to revised models that incorporate the Moderna settlement proceeds, a slightly higher assumed discount rate, modest tweaks to long term profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent research updates focus heavily on the impact of the Moderna settlement, how the proceeds flow through Roivant Sciences' financial model, and what that might mean for valuation versus execution risk.Recent Insider Transactions Derivative • Apr 19CEO & Director notifies of intention to sell stockMatthew Gline intends to sell 290k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of April. If the sale is conducted around the recent share price of US$29.16, it would amount to US$8.4m. Almost all of their compensation in the past year has been non-cash. These sales could comprise a meaningful part of their income for the year. Since June 2025, Matthew's direct individual holding has increased from 59.15k shares to 372.03k. Company insiders have collectively sold US$380m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Apr 07President exercised options and sold US$1.6m worth of stockOn the 31st of March, Mayukh Sukhatme exercised options to acquire 58k shares at no cost and sold these for an average price of US$27.04 per share. This trade did not impact their existing holding. Mayukh now holds 18.68m shares directly in their own name. Company insiders have collectively sold US$376m more than they bought, via options and on-market transactions in the last 12 months.내러티브 업데이트 • Apr 05ROIV: Settlement Cash Will Refocus Story On 2026 Clinical ReadoutsAnalysts have nudged their average price target for Roivant Sciences to $33, reflecting updated models that factor in the $2.25b litigation settlement with Moderna and the removal of what several firms describe as a major overhang on the story. Analyst Commentary Street research on Roivant Sciences has clustered around two core themes: the impact of the US$2.25b litigation settlement and what that means for valuation, and the shift in focus toward the company’s clinical and execution milestones.공시 • Apr 02Roivant Sciences Ltd. Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Roivant Sciences Ltd. announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States, and reported the topline results from Immunovant’s two Phase 3 (GO) clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease (TED). LPP inflammation targets the stem cell-rich bulge region of the hair follicle (the permanent portion responsible for hair growth), resulting in generally irreversible hair loss and permanent scarring. LPP is also associated with other burdensome symptoms, including pain, burning, itching, and scaling and an increased risk of comorbidities such as other autoimmune diseases and skin cancers. There are currently no FDA-approved therapies to treat LPP. Priovant recently began enrolling subjects in a seamless Phase 2b/3 study of brepocitinib in LPP, with the first subjects enrolled in March 2026. This program marks Priovant’s fourth indication in late-stage clinical development, alongside dermatomyositis (DM), non-infectious uveitis (NIU) and cutaneous sarcoidosis (CS). The U.S. Food and Drug Administration (FDA) recently granted Priority Review to brepocitinib’s New Drug Application (NDA) for DM and assigned a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of calendar year 2026. Topline Phase 3 data in NIU and Phase 3 study initiation in CS are expected in the second half of calendar year 2026.Based on the pre-specified statistical analysis plan, the studies failed to meet their primary endpoint of =2mm proptosis responder rate at Week 24, following 12 weeks of high-dose and 12 weeks of low-dose batoclimab treatment. Safety results were consistent with previous findings, and no new safety signals were identified. Patients in the TED studies had greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The subset of hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves’ disease. Immunovant remains focused on rapidly advancing the clinical development of IMVT-1402, an investigational FcRn blocker, across multiple autoimmune diseases with significant unmet need, with Graves’ disease as a key strategic priority. Recent Phase 2 proof-of-concept data highlighted FcRn blockade as a potentially disease-modifying approach in Graves’ disease. Topline data from the potentially registrational studies of IMVT-1402 in Graves’ disease are expected in calendar year 2027.Immunovant intends to review future plans for the development of batoclimab with its partner HanAll Biopharma Co. Ltd. (HanAll) and to provide an update on the program, in conjunction with HanAll, at a future date.Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. President, Chief Investment Officer & Director Mayukh Sukhatme was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions Derivative • Mar 29Independent Director notifies of intention to sell stockMeghan FitzGerald intends to sell 70k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of March. If the sale is conducted around the recent share price of US$27.45, it would amount to US$1.9m. Since September 2025, Meghan has owned 28.44k shares directly. Company insiders have collectively sold US$368m more than they bought, via options and on-market transactions in the last 12 months.내러티브 업데이트 • Mar 22ROIV: Moderna Settlement Cash Sets Up 2026 Clinical Readout RepricingNarrative Update on Roivant Sciences The analyst price target for Roivant Sciences has been adjusted from $32.27 to $33.25. Analysts cite the Moderna litigation settlement, related $2.25b proceeds, and the removal of a major overhang as key supports for their updated models.Recent Insider Transactions Derivative • Mar 19President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of March. If the sale is conducted around the recent share price of US$28.24, it would amount to US$5.6m. Since March 2025, Eric's direct individual holding has increased from 883.70k shares to 1.33m. Company insiders have collectively sold US$372m more than they bought, via options and on-market transactions in the last 12 months.내러티브 업데이트 • Mar 07ROIV: Moderna Settlement Clears Path For 2026 Clinical Readout UpsideAnalysts have nudged their average price target for Roivant Sciences higher to about $32, supported by updated models that factor in the $2.25b Moderna settlement. They view the resolution of the litigation as lifting a major overhang and refocusing attention on upcoming clinical readouts.내러티브 업데이트 • Feb 21ROIV: 2026 Clinical Readouts Are Expected To Unlock Further UpsideRoivant Sciences' analyst price target has increased from $27.00 to about $31.73 as analysts factor in updated assumptions around revenue growth, margin potential and a lower future P/E based on recent Street research. Analyst Commentary Recent Street research shows a cluster of price target increases for Roivant Sciences, with several firms revisiting their models around revenue potential, profitability and valuation multiples.Recent Insider Transactions Derivative • Feb 10President notifies of intention to sell stockMayukh Sukhatme intends to sell 339k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of February. If the sale is conducted around the recent share price of US$26.47, it would amount to US$9.0m. Mayukh now holds 18.84m shares directly in their own name. Company insiders have collectively sold US$293m more than they bought, via options and on-market transactions in the last 12 months.Price Target Changed • Feb 08Price target increased by 7.7% to US$29.09Up from US$27.00, the current price target is an average from 11 analysts. New target price is 13% above last closing price of US$25.82. Stock is up 137% over the past year. The company is forecast to post a net loss per share of US$1.19 next year compared to a net loss per share of US$0.75 last year.Reported Earnings • Feb 07Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: US$0.38 loss per share (further deteriorated from US$0.22 loss in 3Q 2025). Revenue: US$2.00m (down 78% from 3Q 2025). Net loss: US$265.9m (loss widened 69% from 3Q 2025). Revenue missed analyst estimates by 67%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings.공시 • Feb 06Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Interstitial Lung DiseasePulmovant, and a Roivant company announced that it has completed enrollment in the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. Mosliciguat is a potential first-in-class, once-daily, inhaled sGC activator with a differentiated mechanism of action designed to deliver targeted pulmonary vasodilation with limited systemic side effects for the treatment of PH-ILD. Pulmovant completed enrollment of the PHocus clinical trial in under 12 months from first patient dosed, an impressive timeline in clinical development of treatments for PH-ILD. Pulmovaant remains on track to report PHocus topline data in the second half of calendar year 2026. The Phase 2 PHocus clinical study (NCT06635850) is a randomized, double-blind, placebo-controlled, global trial assessing the safety and efficacy of mosliciguat in approximately 120 adult participants with PH-ILD.Mosliciguat is also being evaluated in the Phase 2 PHactor clinical study (NCT07333183), an open-label trial evaluating the tolerability and safety of inhaled mosliciguat in combination with inhaled treprostinil in participants with PH-ILD. The Phase 2 PH focus clinical study (NCT0 6635850) is a randomized. double-blind, placebo- controlled, global trial evaluating the safety and efficacy of Mosliciguat in approximately120 adult participants with PH-ILD; Mosliciguat is also be evaluated in the Phase 2 PHact clinical study (NCT0733183), an open- label trial evaluating the tolerability and Safety of inhaled moslicigUat in combination with inhaled Treprostinil in Participants with PH-ILD. PulmOVant is a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases and is a Roivant company. Pulmovant's first investigational candidate, Mosliciguat, is designed to provide a novel, once- daily, inhaled treatment option for patients with pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD). Mosliciguat is an potential first-in-classsoluble guanylate cyclase activator with a differentiated mechanismof action currently being evaluated in the Phase 2PHocus clinical trial in under 12 years.내러티브 업데이트 • Feb 06ROIV: 2026 Trial Results And IP Litigation Are Expected To Unlock UpsideNarrative Update Analysts have lifted their blended price target on Roivant Sciences by US$3, citing recent Street research that points to ongoing batoclimab Phase 3 trial progress, a clearer 2026 data timeline, and Roivant's position in the royalty dispute backdrop with Moderna. Analyst Commentary Street research on Roivant Sciences is generally constructive, with recent notes focusing on valuation support from batoclimab, the timing of key Phase 3 readouts, and the ongoing royalty dispute backdrop with Moderna.공시 • Jan 24Roivant Sciences Ltd. to Report Q3, 2026 Results on Feb 06, 2026Roivant Sciences Ltd. announced that they will report Q3, 2026 results Pre-Market on Feb 06, 2026내러티브 업데이트 • Jan 22ROIV: 2026 Trial Readouts And IP Litigation Are Expected To Drive UpsideNarrative Update: Roivant Sciences (ROIV) Analysts have modestly raised their average price target on Roivant Sciences to about $27, citing updated assumptions around batoclimab trial timelines into 2026 and Roivant's role in ongoing Moderna IP litigation as key factors behind the revised outlook. Analyst Commentary Recent research points to a mixed but generally constructive view on Roivant Sciences, with attention on batoclimab timing and the evolving relationship with Moderna as key inputs into valuation and execution risk.Recent Insider Transactions Derivative • Jan 13President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of January. If the sale is conducted around the recent share price of US$21.92, it would amount to US$4.4m. Since March 2025, Eric's direct individual holding has increased from 883.70k shares to 1.33m. Company insiders have collectively sold US$290m more than they bought, via options and on-market transactions in the last 12 months.내러티브 업데이트 • Jan 08ROIV: 2026 Clinical Readouts And LNP Litigation Are Expected To Drive UpsideAnalysts have lifted their price expectations for Roivant Sciences, with the blended fair value estimate moving from US$25.64 to about US$27.00 as they weigh updated Phase 3 timelines, a slightly lower discount rate, and higher assumed future P/E multiples, alongside perceived improvements in counter-party credit quality related to ongoing IP litigation. Analyst Commentary Recent Street research on Roivant Sciences reflects a mix of optimism around the pipeline and valuation support, alongside some caution on execution timing and external legal factors.Price Target Changed • Jan 07Price target increased by 10% to US$27.00Up from US$24.55, the current price target is an average from 11 analysts. New target price is 23% above last closing price of US$21.96. Stock is up 99% over the past year. The company is forecast to post a net loss per share of US$1.16 next year compared to a net loss per share of US$0.75 last year.Recent Insider Transactions • Dec 31Chief Financial Officer recently sold US$3.3m worth of stockOn the 23rd of December, Richard Pulik sold around 147k shares on-market at roughly US$22.39 per share. This transaction amounted to 73% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$38m. This was Richard's only on-market trade for the last 12 months.내러티브 업데이트 • Dec 15ROIV: Late Stage Pipeline And LNP Litigation Will Drive Upside Into 2026Analysts have nudged their blended fair value estimate for Roivant Sciences higher, lifting the implied price target by about $1 to approximately $25.64. They are factoring in a richer future earnings multiple and growing confidence in the company’s late stage pipeline and ongoing litigation optionality, despite slightly softer margin and growth assumptions.공시 • Dec 11Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth At 2025 Investor DayRoivant announced positive updates to timing guidance across four key programs: Brepocitinib NDA filing in dermatomyositis (DM) now expected in early calendar year 2026; commercial preparation underway with launch expected early in calendar year 2027; Brepocitinib Phase 3 trial in non-infectious uveitis (NIU) fully enrolled with topline data now expected in the second half of calendar year 2026; commercial preparations underway with launch expected early in fiscal year 2027; Bre pocitinib Phase 3 trials in non-infectious uVEitis (NIU) fully enroll with topline data now expects in the first half of calendar year 2026, and a proof-of-concept trial in cutaneous lupus erythematosus (CLE) Mosliciguat: Enrollment in the ongoing Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) remains on track; Pulmovant plans to report topline data in the second half of calendaryear 2026, previously expected in the second half of fiscal year 2026; previously expected Period 1 data in calendar year 2026 and topline data in calendar year 2027; All other clinical development timelines remain on track, including potentially registrational trials in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjogren's disease (SjD), and a proof-of- concept trial in cutaneous lupUS erythematosus ("CLE") Mosliciguat") Enrollment in the ongoing Phase2 trial of moslicigu at pulmonary hypertension associated with interstitial lupus erytheMatosus (CLE). Pulmovant also expects to imminently initiate a Phase 2 study (n=20) evaluating mosliciguat in combination with inhaled treprostinil in patients with PH-ILD Genevant. In the US Moderna litigation, a jury trial has been scheduled for March 2026. Awaiting court scheduling in the Pfizer/BioNTech litigation. Initial court hearings and rulings in the ex-US Moderna litigation expected in calendar year 2026.Recent Insider Transactions Derivative • Dec 10President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of December. If the sale is conducted around the recent share price of US$20.85, it would amount to US$4.2m. Since December 2024, Eric's direct individual holding has increased from 438.01k shares to 1.17m. Company insiders have collectively sold US$153m more than they bought, via options and on-market transactions in the last 12 months.내러티브 업데이트 • Nov 30ROIV: Positive Phase 3 Data Will Drive Shares Into 2026 And BeyondThe analyst price target for Roivant Sciences has increased from approximately $23.27 to $24.55. Analysts cite stronger revenue growth forecasts and recent positive clinical trial updates as factors driving an improved company outlook.Recent Insider Transactions • Nov 19Insider recently sold US$38m worth of stockOn the 17th of November, Vivek Ramaswamy sold around 2m shares on-market at roughly US$20.46 per share. This transaction amounted to 3.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$110m more than they bought in the last 12 months.내러티브 업데이트 • Nov 16ROIV: Upcoming Data From Phase 3 Trials Will Drive Shares HigherAnalysts have raised their fair value estimate for Roivant Sciences from $20.86 to $23.27 per share. They cite strong Phase 3 trial results, continued clinical progress, and anticipated upcoming catalysts as key factors behind the updated price target.Reported Earnings • Nov 12Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2026 results: US$0.17 loss per share (improved from US$0.25 loss in 2Q 2025). Revenue: US$1.57m (down 65% from 2Q 2025). Net loss: US$113.5m (loss narrowed 39% from 2Q 2025). Revenue missed analyst estimates by 75%. Earnings per share (EPS) exceeded analyst estimates by 49%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions Derivative • Nov 09President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of November. If the sale is conducted around the recent share price of US$20.22, it would amount to US$4.0m. Since December 2024, Eric's direct individual holding has increased from 438.01k shares to 1.17m. Company insiders have collectively sold US$113m more than they bought, via options and on-market transactions in the last 12 months.내러티브 업데이트 • Oct 31ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term OutlookThe analyst price target for Roivant Sciences has been increased by approximately $0.82 to $20.86 per share. Analysts cite strong Phase 3 trial results and a positive outlook for brepocitinib as key drivers of their upward revisions.공시 • Oct 28Roivant Sciences Ltd. to Report Q2, 2026 Results on Nov 10, 2025Roivant Sciences Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025내러티브 업데이트 • Oct 17Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks RemainAnalysts have recently increased their price targets for Roivant Sciences. The consensus has moved higher by several dollars per share as positive Phase 3 results for brepocitinib and progress in litigation bolster confidence in the company's outlook.Recent Insider Transactions Derivative • Oct 07President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 171k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of October. If the sale is conducted around the recent share price of US$16.34, it would amount to US$2.8m. Since December 2024, Eric's direct individual holding has increased from 438.01k shares to 1.17m. Company insiders have collectively sold US$108m more than they bought, via options and on-market transactions in the last 12 months.내러티브 업데이트 • Oct 03Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks RemainThe analyst consensus price target for Roivant Sciences has increased from $18.30 to $20.05. Analysts cite strong Phase 3 dermatomyositis data and anticipated commercial potential as key drivers for the upward revision.Recent Insider Transactions • Sep 25President & CEO of Immunovant recently sold US$17m worth of stockOn the 23rd of September, Eric Venker sold around 1m shares on-market at roughly US$14.90 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$22m. This was Eric's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Sep 21President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 684k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of September. If the sale is conducted around the recent share price of US$14.95, it would amount to US$10m. Since December 2024, Eric's direct individual holding has increased from 438.01k shares to 1.31m. Company insiders have collectively sold US$155m more than they bought, via options and on-market transactions in the last 12 months.Price Target Changed • Sep 18Price target increased by 16% to US$19.64Up from US$17.00, the current price target is an average from 11 analysts. New target price is 30% above last closing price of US$15.09. Stock is up 27% over the past year. The company is forecast to post a net loss per share of US$1.35 next year compared to a net loss per share of US$0.75 last year.내러티브 업데이트 • Sep 18Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks RemainAnalysts have raised Roivant Sciences’ price target from $17.00 to $18.30, citing bullish expectations for favorable Phase 3 brepocitinib data in dermatomyositis as a key catalyst and reflecting increased optimism around near-term pipeline milestones. Analyst Commentary Bullish analysts expect favorable risk/reward ahead of brepocitinib Phase 3 data in dermatomyositis, with key results anticipated in September.공시 • Sep 17Roivant and Priovant Announce Positive Phase 3 Valor Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in DermatomyositisRoivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM). On the primary endpoint, brepocitinib 30 mg achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo (p=0.0006), even with nearly twice as many patients coming off background steroid on brepocitinib30 mg compared to placebo. More than two thirds of brepocitinib 300 mg patients experienced at least a moderate response (TIS40), and nearly half experienced a major response (TIS60). Consistent dose response was seen between 30 mg and 15 mg dose arms, establishing 30 mg dose as optimal in this setting. Safety profile was consistent with previous brepocitinib and NDA filing is planned for calendar 1H 2026. The observed brepocitinib 25 mg safety profile was consistent with previous bre p<0.0006. The observed brepoc itinib 30 mg safety profile was consistent with previously brepocitinib clinical trials. Adverse events of special interest (AESIs), which included malignancy, cardiovascular events, and thromboembolic events, did not occur with greater frequency in the brepocitinib 50 mg arm than the placebo arm. Priovant plans to file an NDA for brepocit in dermatomyositis in the first half of 2026.공시 • Sep 15ProofPilot, Inc. acquired Lokavant, Inc.ProofPilot, Inc. acquired Lokavant, Inc. on September 15, 2025. ProofPilot, Inc. completed the acquisition of Lokavant, Inc. on September 15, 2025.Recent Insider Transactions • Sep 08Insider recently sold US$22m worth of stockOn the 5th of September, Vivek Ramaswamy sold around 2m shares on-market at roughly US$12.65 per share. This transaction amounted to 3.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$106m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Aug 21President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of August. If the sale is conducted around the recent share price of US$11.72, it would amount to US$1.2m. Since September 2024, Eric's direct individual holding has increased from 266.07k shares to 1.31m. Company insiders have collectively sold US$131m more than they bought, via options and on-market transactions in the last 12 months.Major Estimate Revision • Aug 18Consensus revenue estimates fall by 17%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$28.5m to US$23.7m. Forecast losses increased from -US$1.29 to -US$1.36 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$17.11. Share price rose 6.1% to US$11.85 over the past week.Reported Earnings • Aug 12First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: US$0.33 loss per share (down from US$0.008 profit in 1Q 2025). Revenue: US$2.17m (down 73% from 1Q 2025). Net loss: US$223.4m (down US$229.6m from profit in 1Q 2025). Revenue missed analyst estimates by 69%. Earnings per share (EPS) also missed analyst estimates by 26%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 41% per year.공시 • Aug 12Roivant Sciences Ltd. (NasdaqGS:ROIV) announces an Equity Buyback for $500 million worth of its shares.Roivant Sciences Ltd. (NasdaqGS:ROIV) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its common shares.공시 • Jul 30Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2025Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2025. Location: royal lancaster london hotel, lancaster terrace, london w2 2ty, united kingdom, United Kingdom공시 • Jul 29Roivant Sciences Ltd. to Report Q1, 2026 Results on Aug 11, 2025Roivant Sciences Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Aug 11, 2025Recent Insider Transactions Derivative • Jul 22President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of July. If the sale is conducted around the recent share price of US$11.52, it would amount to US$1.2m. Since September 2024, Eric's direct individual holding has increased from 266.07k shares to 1.31m. Company insiders have collectively sold US$131m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Jun 08Insider recently sold US$8.5m worth of stockOn the 6th of June, Vivek Ramaswamy sold around 748k shares on-market at roughly US$11.30 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$10m. Insiders have been net sellers, collectively disposing of US$71m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Jun 03President & COO notifies of intention to sell stockEric Venker intends to sell 434k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of June. If the sale is conducted around the recent share price of US$11.07, it would amount to US$4.8m. Since June 2024, Eric's direct individual holding has increased from 239.53k shares to 853.40k. Company insiders have collectively sold US$102m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • May 30Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: US$0.75 loss per share (down from US$5.55 profit in FY 2024). Revenue: US$29.1m (down 77% from FY 2024). Net loss: US$545.0m (down 113% from profit in FY 2024). Revenue missed analyst estimates by 79%. Earnings per share (EPS) exceeded analyst estimates by 27%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions Derivative • May 21President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of May. If the sale is conducted around the recent share price of US$10.95, it would amount to US$1.1m. Since June 2024, Eric's direct individual holding has increased from 239.53k shares to 892.55k. Company insiders have collectively sold US$102m more than they bought, via options and on-market transactions in the last 12 months.공시 • May 16Roivant Sciences Ltd. to Report Q4, 2025 Results on May 29, 2025Roivant Sciences Ltd. announced that they will report Q4, 2025 results on May 29, 2025Recent Insider Transactions • May 11Insider recently sold US$10m worth of stockOn the 7th of May, Vivek Ramaswamy sold around 899k shares on-market at roughly US$11.27 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$62m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Apr 23President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of April. If the sale is conducted around the recent share price of US$10.22, it would amount to US$1.0m. Since June 2024, Eric's direct individual holding has increased from 239.53k shares to 883.70k. Company insiders have collectively sold US$91m more than they bought, via options and on-market transactions in the last 12 months.Seeking Alpha • Apr 23Roivant Sciences: Primed For Growth With A De-Risked PipelineSummary Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs. Current market valuations significantly undervalue Roivant's potential peak sales, suggesting substantial upside potential given its strong cash position and de-risked late-stage pipeline. Read the full article on Seeking AlphaRecent Insider Transactions Derivative • Mar 21President & COO notifies of intention to sell stockEric Venker intends to sell 650k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of March. If the sale is conducted around the recent share price of US$10.95, it would amount to US$7.1m. Since June 2024, Eric's direct individual holding has increased from 239.53k shares to 622.55k. Company insiders have collectively sold US$93m more than they bought, via options and on-market transactions in the last 12 months.공시 • Feb 22Roivant Sciences Ltd. Announces Stepping Down of Rakhi Kumar as Principal Accounting OfficerRoivant Sciences Ltd. announced stepping down of Rakhi Kumar as Principal Accounting Officer, effective February 20, 2025.Recent Insider Transactions • Feb 20Chief Accounting Officer recently sold US$417k worth of stockOn the 13th of February, Rakhi Kumar sold around 40k shares on-market at roughly US$10.43 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$52m more than they bought in the last 12 months.Major Estimate Revision • Feb 17Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from US$119.5m to US$141.3m. Forecast losses expected to reduce from -US$0.736 to -US$0.329 per share. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target broadly unchanged at US$16.00. Share price fell 2.1% to US$10.56 over the past week.Recent Insider Transactions Derivative • Feb 13President & COO notifies of intention to sell stockEric Venker intends to sell 600k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of February. If the sale is conducted around the recent share price of US$10.50, it would amount to US$6.3m. Since March 2024, Eric's direct individual holding has increased from 204.81k shares to 449.12k. Company insiders have collectively sold US$88m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Feb 10Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.22 loss per share (down from US$6.37 profit in 3Q 2024). Revenue: US$9.02m (down 76% from 3Q 2024). Net loss: US$157.6m (down 103% from profit in 3Q 2024). Revenue exceeded analyst estimates by 90%. Earnings per share (EPS) also surpassed analyst estimates by 178%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Seeking Alpha • Feb 05Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)Summary Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results. Company maintains strong financials with $5.4B in cash/investments and 6-year runway at current burn rate of $76M monthly. I am downgrading to "hold" given the unclear path to profitability and challenges in differentiating clinical assets, though I still see value in a barbell portfolio. Read the full article on Seeking Alpha공시 • Jan 30Roivant Sciences Ltd. to Report Q3, 2025 Results on Feb 10, 2025Roivant Sciences Ltd. announced that they will report Q3, 2025 results on Feb 10, 2025새로운 내러티브 • Jan 26Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas. Recent Insider Transactions Derivative • Jan 22President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of January. If the sale is conducted around the recent share price of US$11.28, it would amount to US$1.1m. Since March 2024, Eric's direct individual holding has increased from 204.81k shares to 438.01k. Company insiders have collectively sold US$88m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Dec 19President notifies of intention to sell stockMayukh Sukhatme intends to sell 413k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of December. If the sale is conducted around the recent share price of US$12.05, it would amount to US$5.0m. Since December 2023, Mayukh's direct individual holding has decreased from 3.29m shares to 0. Company insiders have collectively sold US$109m more than they bought, via options and on-market transactions in the last 12 months.Seeking Alpha • Dec 04Roivant Sciences: A Biotech Growth Play With Major AmbitionsSummary Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat position Roivant for significant clinical and commercial milestones by 2025. Strategic divestitures, like Dermavant's sale to Organon for $1.2 billion, support shareholder value through share buybacks and bolster financial stability. ROIV has legal risks from ongoing LNP technology lawsuits, but favorable outcomes could significantly improve its long-term outlook as well. Despite its clinical, legal, and cash burn risks, Roivant's diversified late-stage pipeline and robust financials promise significant growth potential. Read the full article on Seeking Alpha공시 • Dec 03Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisKinevant Sciences announced its Phase 2 study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. The Phase 2 RESOLVE-Lung study (NCT05314517) evaluated the efficacy and safety of namilumab, an investigational anti-GM-CSF monoclonal antibody administered once-monthly as a subcutaneous injection, in participants with chronic active pulmonary sarcoidosis. Primary Endpoint Details: Namilumab failed to meet the primary endpoint of proportion of subjects with a Rescue Event during the double-blind period. Secondary Endpoints Details: Secondary efficacy endpoints, including change in percent predicted forced vital capacity, corticosteroid tapering success, and change in the patient reported King’s Sarcoidosis Questionnaire failed to show a treatment benefit consistent with the primary endpoint. Safety Details: The safety profile of namilumab in RESOLVE-Lung remains similar to previous studies. With these results, Kinevant will be discontinuing further development of namilumab for the treatment of sarcoidosis. Kinevant is committed to publishing the results of RESOLVE-Lung to inform future sarcoidosis research. The RESOLVE-Lung study is a Phase 2 randomized, double-blind, placebo-controlled study of namilumab for the treatment of pulmonary sarcoidosis at sites in the U.S. and Europe. The study enrolled 107 patients with pulmonary sarcoidosis considered to have chronic, active disease not well-controlled despite available therapeutic options. Patients in the study received a once-monthly subcutaneous injection of namilumab or placebo (following the initial dosing period) for approximately six months. All patients who complete the 26-week double-blind treatment period were eligible to participate in a 28-week open-label extension treatment period on namilumab. The primary endpoint of this study was proportion of subjects with a Rescue Event during the double-blind period. Rescue Event was defined as clinically significant worsening of a subject’s sarcoidosis requiring treatment, failure to adhere to the protocol defined OCS taper, or premature discontinuation from the study associated with lack of benefit during the double-blind treatment period. Study eligibility did not require subjects to be on high dose corticosteroids. If subjects were on >5mg/day of oral corticosteroid (OCS) at baseline, they were required to taper down to 5mg/day 8-10 weeks after randomization. If patients were on an immunosuppressive therapy (IST), they were required to stop the IST at randomization. Notably, all subjects enrolled had evidence of active pulmonary sarcoidosis disease, defined as a positive HRCT scan, significant lung inflammation on PET, and moderate to severe self-reported breathlessness. Pulmonary sarcoidosis is a lung disease characterized by the presence of granulomas (clumps of immune cells) of unknown etiology that can cause breathlessness, fatigue, and pain. The resulting inflammation, if not effectively treated, can result in lung tissue scarring (fibrosis), lung dysfunction, and eventually lung failure. Approximately 50% of diagnosed patients require chronic therapy to treat symptoms and prevent progression. Oral steroids (e.g., prednisone) and off-label immunosuppressive therapies (e.g., methotrexate) are first- and second-line therapies respectively for sarcoidosis; however, these therapeutic options are often not effective or can be accompanied by serious side effects. Approximately 200,000 people in the U.S. (and more than 1 million worldwide) are estimated to have sarcoidosis, an immune-mediated inflammatory disease that can affect any organ in the body, with about 90% of cases involving the lung. Granulocyte macrophage colony stimulating factor (GM-CSF) is a pro-inflammatory cytokine over-expressed in several inflammatory diseases, including sarcoidosis. GM-CSF mediated pro-inflammatory signaling is thought to play a central role in recruitment of macrophages and monocytes to the lung and to trigger a granulomatous response, including the fusion of macrophages into multinucleated giant cells. Namilumab is an anti-GM-CSF monoclonal antibody formulated to be administered once-monthly as a subcutaneous injection being investigated for the treatment of pulmonary sarcoidosis.Recent Insider Transactions Derivative • Nov 21President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of November. If the sale is conducted around the recent share price of US$11.32, it would amount to US$1.1m. Since December 2023, Eric's direct individual holding has increased from 162.38k shares to 274.92k. Company insiders have collectively sold US$109m more than they bought, via options and on-market transactions in the last 12 months.Major Estimate Revision • Nov 19Consensus revenue estimates decrease by 36%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$194.0m to US$125.0m. EPS estimate unchanged at -US$0.727 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$16.94 to US$16.21. Share price fell 5.5% to US$11.16 over the past week.New Risk • Nov 14New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 1,958% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 53% per year for the foreseeable future. High level of non-cash earnings (1,958% accrual ratio). Minor Risk Significant insider selling over the past 3 months (US$52m sold).Reported Earnings • Nov 13Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: US$0.25 loss per share (improved from US$0.40 loss in 2Q 2024). Revenue: US$4.48m (down 88% from 2Q 2024). Net loss: US$187.1m (loss narrowed 39% from 2Q 2024). Revenue missed analyst estimates by 43%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.공시 • Oct 30Roivant Sciences Ltd. to Report Q2, 2025 Results on Nov 12, 2024Roivant Sciences Ltd. announced that they will report Q2, 2025 results on Nov 12, 2024공시 • Oct 28Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others.Organon & Co. (NYSE:OGN) entered into an Agreement and Plan of Merger to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion on September 17, 2024. A cash consideration, Organon to acquire Dermavant for aggregate consideration of up to approximately $1.2 billion, comprising (i) a payment of $175 million payable at the closing of the Merger, subject to certain adjustments, (ii) a $75 million milestone payment payable upon FDA approval of VTAMA product for the treatment of atopic dermatitis and (iii) up to $950 million in additional milestone payments payable upon achievement of certain tiered net sales amounts with respect to the Product, each less than or equal to $1 billion. Additionally, Organon has agreed to make tiered royalty payments of (x) low-to-mid single digit percentages with respect to annual net sales of the Product up to $1 billion and (y) 30% with respect to annual net sales of the Product above $1 billion. Upon closing of the transaction, as part of the purchase price consideration, Organon would assume Dermavant liabilities with an approximate value of $286 million reported by Roivant as of June 30, 2024, which would be subject to fair value accounting by Organon. Dermavant owns the rights to VTAMA cream globally excluding China and has out licensed Japan rights. Pursuant to the terms of the Merger Agreement, Dermavant continuing as the surviving company and a wholly owned subsidiary of Organon. The boards of directors of the Company and of Dermavant each approved the entry into the Merger Agreement and the consummation of the Merger. Concurrently with the entry into the Merger Agreement, the Merger Agreement and the Merger were approved by written consent of shareholders constituting at least 75% of the aggregate voting rights of Dermavant’s issued and outstanding common and preference shares. Completion of the transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to be modestly dilutive to Adjusted EBITDA in 2025, turning accretive in 2026. Organon expects net leverage to be elevated above 4.0x as a result of the transaction. The transaction is not expected to result in a revision to Organon’s capital allocation priorities. Company and Organon has the right to terminate the Merger Agreement and abandon the Merger in the event that the Merger has not been consummated by January 5, 2025 due to failure to satisfy certain antitrust-related conditions. Closing of the transaction is currently expected to take place in the fourth quarter of 2024. Damien Zoubek, Jenny Hochenberg and Tomas Rua, Jeff Jay, Lori Goodman, Steven Matays, Meghan Rissmiller and Rod Carlton, Charles Ramsey, Christine Lyon and Brock Dahl and Stephanie Brown-Cripps of Freshfields Bruckhaus Deringer LLP acted as legal advisor for Roivant Sciences Ltd and Dermavant Sciences Ltd. Goldman Sachs & Co. LLC acted as financial advisor for Roivant Sciences Ltd. Catherine Dargan and Patrick Manchester of Covington & Burling LLP acted as legal advisor for Organon & Co. Deloitte & Touche LLP acted as accountant to Roivant Sciences Ltd. Conyers Dill & Pearman LLP acted as Bermuda legal advisor for Roivant Sciences Ltd. Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others on October 28, 2024.Recent Insider Transactions Derivative • Oct 23President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of October. If the sale is conducted around the recent share price of US$11.65, it would amount to US$1.2m. Since December 2023, Eric's direct individual holding has increased from 162.38k shares to 266.07k. Company insiders have collectively sold US$108m more than they bought, via options and on-market transactions in the last 12 months.Seeking Alpha • Oct 22Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring VolatilitySummary Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant’s batoclimab in Phase 3 trials and namilumab in a Phase 2 trial, though drug candidate performance remains a critical risk factor. Litigation against Moderna and Pfizer, coupled with Techbio advancements, could drive future valuation. Read the full article on Seeking AlphaRecent Insider Transactions Derivative • Oct 03Independent Director notifies of intention to sell stockDaniel Gold intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 24th of September. If the sale is conducted around the recent share price of US$11.63, it would amount to US$18m. Since March 2024, Daniel's direct individual holding has decreased from 9.91m shares to 6.43m. Company insiders have collectively sold US$116m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Sep 26CEO & Director recently sold US$5.1m worth of stockOn the 23rd of September, Matthew Gline sold around 433k shares on-market at roughly US$11.79 per share. This transaction amounted to 2.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Matthew's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Sep 25CEO & Director notifies of intention to sell stockMatthew Gline intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of September. If the sale is conducted around the recent share price of US$11.79, it would amount to US$23m. For the year to March 2021, Matthew's total compensation was 98% salary and 2% non-salary. Since September 2023, Matthew's direct individual holding has increased from 645.38k shares to 931.79k. Company insiders have collectively sold US$55m more than they bought, via options and on-market transactions in the last 12 months.공시 • Sep 18Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion.Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) from and others for approximately $1.2 billion on September 18, 2024. A cash consideration will be paid by Organon & Co. Organon has agreed to acquire Dermavant for aggregate consideration of up to approximately $1.2 billion, with an upfront payment of $175 million and a $75 million milestone payment upon regulatory approval in AD, as well as payments of up to $950 million for the achievements of certain commercial milestones. Upon closing of the transaction, as part of the purchase price consideration, Organon would assume Dermavant liabilities with an approximate value of $286 million reported by Roivant as of June 30, 2024, which would be subject to fair value accounting by Organon. In addition, Organon will pay Dermavant shareholders tiered royalties on net sales. Dermavant owns the rights to VTAMA cream globally excluding China and has out licensed Japan rights. Completion of the transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Closing of the transaction is currently expected to take place in the fourth quarter of 2024. The transaction is expected to be modestly dilutive to Adjusted EBITDA in 2025, turning accretive in 2026. Organon expects net leverage to be elevated above 4.0x as a result of the transaction. The transaction is not expected to result in a revision to Organon’s capital allocation priorities. Freshfields Bruckhaus Deringer LLP acted as legal advisor for Roivant Sciences Ltd. Goldman Sachs & Co. LLC acted as financial advisor for Roivant Sciences Ltd. Covington & Burling LLP acted as legal advisor for Organon & Co.Seeking Alpha • Aug 22Roivant Sciences: Inherently Risky Business Model, But Track Record ImpressesSummary Roivant Sciences stock has risen significantly since my initial coverage in 2022, with a positive market response to fiscal year 2025 Q1 earnings. Roivant operates by creating "nimble subsidiaries to develop and commercialize medicines", with a focus on unearthing strong drug candidates for lucrative exits. Key drugs in Roivant's pipeline include VTAMA, Batoclimab, and Breproctinib, each facing competition and uncertainties in their respective markets. Roivant was founded by a venture capitalist and is currently run by an ex-Goldman Sachs banker - after securing the $7bn exit of Televant to Roche last year, the company is cash rish. Across the next 12 months, most of Roivant's key assets will read out key data in key indications - we are at the beginning of a "make-or-break" year for the company that ought to create significant price volatility. Read the full article on Seeking AlphaMajor Estimate Revision • Aug 16Consensus revenue estimates increase by 18%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$147.7m to US$174.2m. EPS estimate unchanged from -US$0.70 at last update. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target of US$16.67 unchanged from last update. Share price rose 4.2% to US$11.31 over the past week.New Risk • Aug 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 1,252% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 60% per year for the foreseeable future. High level of non-cash earnings (1,252% accrual ratio).Reported Earnings • Aug 09First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.13 (up from US$0.38 loss in 1Q 2024). Revenue: US$55.1m (up 155% from 1Q 2024). Net income: US$95.3m (up US$387.1m from 1Q 2024). Revenue exceeded analyst estimates by 86%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.공시 • Jul 29Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2024Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2024. Location: royal lancaster london hotel, lancaster terrace, london w2 2ty, united kingdom on, london United States매출 및 비용 세부 내역Roivant Sciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGS:ROIV 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 268-300606031 Dec 2513-809661030 Sep 2520-701539030 Jun 2523-775605031 Mar 2529-545570031 Dec 2431-402442030 Sep 24374,910490030 Jun 24364,879382031 Mar 24334,664381031 Dec 23514,579406030 Sep 2353-927474030 Jun 2361-1,001543031 Mar 2332-783383031 Dec 2243-1,245614030 Sep 2250-1,178561030 Jun 2252-1,095491031 Mar 2255-845425031 Dec 2161-1,085367030 Sep 2143-1,061314030 Jun 2130-888286031 Mar 2124-809260031 Dec 2072-360259-19931 Mar 2068-456336031 Mar 192-613237513양질의 수익: ROIV 은(는) 현재 수익성이 없습니다.이익 마진 증가: ROIV는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ROIV는 수익성이 없지만 지난 5년 동안 연평균 24.5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ROIV의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ROIV은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ROIV는 현재 수익성이 없으므로 자본 수익률이 음수(-7.52%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 12:43종가2026/05/22 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Roivant Sciences Ltd.는 18명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관William PickeringBernsteinChi Meng FongBofA Global ResearchPrakhar AgrawalCantor Fitzgerald & Co.15명의 분석가 더 보기
Reported Earnings • May 21Full year 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2026 results: US$0.43 loss per share (improved from US$0.75 loss in FY 2025). Net loss: US$299.8m (loss narrowed 45% from FY 2025). Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) exceeded analyst estimates by 57%. Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings.
공시 • May 12Roivant Sciences Ltd. to Report Q4, 2026 Results on May 20, 2026Roivant Sciences Ltd. announced that they will report Q4, 2026 results Pre-Market on May 20, 2026
Reported Earnings • Feb 07Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: US$0.38 loss per share (further deteriorated from US$0.22 loss in 3Q 2025). Revenue: US$2.00m (down 78% from 3Q 2025). Net loss: US$265.9m (loss widened 69% from 3Q 2025). Revenue missed analyst estimates by 67%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings.
공시 • Jan 24Roivant Sciences Ltd. to Report Q3, 2026 Results on Feb 06, 2026Roivant Sciences Ltd. announced that they will report Q3, 2026 results Pre-Market on Feb 06, 2026
Reported Earnings • Nov 12Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2026 results: US$0.17 loss per share (improved from US$0.25 loss in 2Q 2025). Revenue: US$1.57m (down 65% from 2Q 2025). Net loss: US$113.5m (loss narrowed 39% from 2Q 2025). Revenue missed analyst estimates by 75%. Earnings per share (EPS) exceeded analyst estimates by 49%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Oct 28Roivant Sciences Ltd. to Report Q2, 2026 Results on Nov 10, 2025Roivant Sciences Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025
Recent Insider Transactions Derivative • 7hPresident & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of May. If the sale is conducted around the recent share price of US$30.27, it would amount to US$6.1m. Since June 2025, Eric's direct individual holding has increased from 1.31m shares to 1.33m. Company insiders have collectively sold US$382m more than they bought, via options and on-market transactions in the last 12 months.
Price Target Changed • May 24Price target increased by 8.2% to US$38.63Up from US$35.71, the current price target is an average from 12 analysts. New target price is 29% above last closing price of US$29.96. Stock is up 176% over the past year. The company is forecast to post a net loss per share of US$1.14 next year compared to a net loss per share of US$0.43 last year.
속보 • May 22Roivant Sciences Turns Profitable as Brepocitinib Launch and Key Drug Data Await Regulatory DecisionsRoivant Sciences swung to profitability in Q4 FY 2026, reversing an attributable net loss from the prior year, which coincided with a roughly 15% move higher in the stock. The company is targeting a commercial launch of oral autoimmune therapy brepocitinib by the end of September, following FDA acceptance and a target action date in Q3. Roivant reported encouraging preliminary open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis and is advancing a Phase II study of inhaled mosliciguat for pulmonary hypertension associated with interstitial lung disease, with top-line data planned for the second half of 2026. The shift to profitability, alongside advancing late-stage and mid-stage drug programs, highlights how much of the story is tied to successful execution on upcoming regulatory and clinical milestones. Investors following Roivant will likely focus on the brepocitinib launch timeline, future data updates for IMVT-1402 and mosliciguat, and the risks that delays or weaker-than-expected clinical results could have on sentiment.
Reported Earnings • May 21Full year 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2026 results: US$0.43 loss per share (improved from US$0.75 loss in FY 2025). Net loss: US$299.8m (loss narrowed 45% from FY 2025). Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) exceeded analyst estimates by 57%. Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings.
Seeking Alpha • May 21Roivant: Immunovant's Rheumatoid Arthritis Win Validates The BuySummary Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant’s IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV’s financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability. Risks include late-stage trial failure, competition, regulatory setbacks, pricing pressure, premium valuation, and complexity in valuing the parent across its 'vants.' Read the full article on Seeking Alpha
내러티브 업데이트 • May 19ROIV: Settlement Windfall Will Shift Focus Toward 2026 Clinical ReadoutsAnalysts have increased their average price target on Roivant Sciences by about $0.04 to $35.71, citing updated models that factor in litigation settlement proceeds, the brepocitinib priority review and a lower assumed discount rate, along with adjusted profit margin and future P/E assumptions. Analyst Commentary Recent research updates on Roivant Sciences show a mix of optimism around litigation proceeds and key pipeline milestones, alongside some caution around how much of this is already reflected in current valuations.
공시 • May 12Roivant Sciences Ltd. to Report Q4, 2026 Results on May 20, 2026Roivant Sciences Ltd. announced that they will report Q4, 2026 results Pre-Market on May 20, 2026
Recent Insider Transactions Derivative • Apr 26President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of April. If the sale is conducted around the recent share price of US$29.59, it would amount to US$5.9m. Since June 2025, Eric's direct individual holding has increased from 1.31m shares to 1.33m. Company insiders have collectively sold US$388m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Apr 22CEO & Director recently sold US$8.4m worth of stockOn the 16th of April, Matthew Gline sold around 290k shares on-market at roughly US$29.16 per share. This transaction amounted to 78% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Matthew has been a net seller over the last 12 months, reducing personal holdings by US$8.4m.
내러티브 업데이트 • Apr 21ROIV: Settlement Cash Will Shift Focus Toward 2026 Late Stage ReadoutsThe updated analyst price target for Roivant Sciences moves from $33.25 to about $35.67, with analysts pointing to revised models that incorporate the Moderna settlement proceeds, a slightly higher assumed discount rate, modest tweaks to long term profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent research updates focus heavily on the impact of the Moderna settlement, how the proceeds flow through Roivant Sciences' financial model, and what that might mean for valuation versus execution risk.
Recent Insider Transactions Derivative • Apr 19CEO & Director notifies of intention to sell stockMatthew Gline intends to sell 290k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of April. If the sale is conducted around the recent share price of US$29.16, it would amount to US$8.4m. Almost all of their compensation in the past year has been non-cash. These sales could comprise a meaningful part of their income for the year. Since June 2025, Matthew's direct individual holding has increased from 59.15k shares to 372.03k. Company insiders have collectively sold US$380m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Apr 07President exercised options and sold US$1.6m worth of stockOn the 31st of March, Mayukh Sukhatme exercised options to acquire 58k shares at no cost and sold these for an average price of US$27.04 per share. This trade did not impact their existing holding. Mayukh now holds 18.68m shares directly in their own name. Company insiders have collectively sold US$376m more than they bought, via options and on-market transactions in the last 12 months.
내러티브 업데이트 • Apr 05ROIV: Settlement Cash Will Refocus Story On 2026 Clinical ReadoutsAnalysts have nudged their average price target for Roivant Sciences to $33, reflecting updated models that factor in the $2.25b litigation settlement with Moderna and the removal of what several firms describe as a major overhang on the story. Analyst Commentary Street research on Roivant Sciences has clustered around two core themes: the impact of the US$2.25b litigation settlement and what that means for valuation, and the shift in focus toward the company’s clinical and execution milestones.
공시 • Apr 02Roivant Sciences Ltd. Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Roivant Sciences Ltd. announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States, and reported the topline results from Immunovant’s two Phase 3 (GO) clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease (TED). LPP inflammation targets the stem cell-rich bulge region of the hair follicle (the permanent portion responsible for hair growth), resulting in generally irreversible hair loss and permanent scarring. LPP is also associated with other burdensome symptoms, including pain, burning, itching, and scaling and an increased risk of comorbidities such as other autoimmune diseases and skin cancers. There are currently no FDA-approved therapies to treat LPP. Priovant recently began enrolling subjects in a seamless Phase 2b/3 study of brepocitinib in LPP, with the first subjects enrolled in March 2026. This program marks Priovant’s fourth indication in late-stage clinical development, alongside dermatomyositis (DM), non-infectious uveitis (NIU) and cutaneous sarcoidosis (CS). The U.S. Food and Drug Administration (FDA) recently granted Priority Review to brepocitinib’s New Drug Application (NDA) for DM and assigned a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of calendar year 2026. Topline Phase 3 data in NIU and Phase 3 study initiation in CS are expected in the second half of calendar year 2026.Based on the pre-specified statistical analysis plan, the studies failed to meet their primary endpoint of =2mm proptosis responder rate at Week 24, following 12 weeks of high-dose and 12 weeks of low-dose batoclimab treatment. Safety results were consistent with previous findings, and no new safety signals were identified. Patients in the TED studies had greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The subset of hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves’ disease. Immunovant remains focused on rapidly advancing the clinical development of IMVT-1402, an investigational FcRn blocker, across multiple autoimmune diseases with significant unmet need, with Graves’ disease as a key strategic priority. Recent Phase 2 proof-of-concept data highlighted FcRn blockade as a potentially disease-modifying approach in Graves’ disease. Topline data from the potentially registrational studies of IMVT-1402 in Graves’ disease are expected in calendar year 2027.Immunovant intends to review future plans for the development of batoclimab with its partner HanAll Biopharma Co. Ltd. (HanAll) and to provide an update on the program, in conjunction with HanAll, at a future date.
Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. President, Chief Investment Officer & Director Mayukh Sukhatme was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions Derivative • Mar 29Independent Director notifies of intention to sell stockMeghan FitzGerald intends to sell 70k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of March. If the sale is conducted around the recent share price of US$27.45, it would amount to US$1.9m. Since September 2025, Meghan has owned 28.44k shares directly. Company insiders have collectively sold US$368m more than they bought, via options and on-market transactions in the last 12 months.
내러티브 업데이트 • Mar 22ROIV: Moderna Settlement Cash Sets Up 2026 Clinical Readout RepricingNarrative Update on Roivant Sciences The analyst price target for Roivant Sciences has been adjusted from $32.27 to $33.25. Analysts cite the Moderna litigation settlement, related $2.25b proceeds, and the removal of a major overhang as key supports for their updated models.
Recent Insider Transactions Derivative • Mar 19President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of March. If the sale is conducted around the recent share price of US$28.24, it would amount to US$5.6m. Since March 2025, Eric's direct individual holding has increased from 883.70k shares to 1.33m. Company insiders have collectively sold US$372m more than they bought, via options and on-market transactions in the last 12 months.
내러티브 업데이트 • Mar 07ROIV: Moderna Settlement Clears Path For 2026 Clinical Readout UpsideAnalysts have nudged their average price target for Roivant Sciences higher to about $32, supported by updated models that factor in the $2.25b Moderna settlement. They view the resolution of the litigation as lifting a major overhang and refocusing attention on upcoming clinical readouts.
내러티브 업데이트 • Feb 21ROIV: 2026 Clinical Readouts Are Expected To Unlock Further UpsideRoivant Sciences' analyst price target has increased from $27.00 to about $31.73 as analysts factor in updated assumptions around revenue growth, margin potential and a lower future P/E based on recent Street research. Analyst Commentary Recent Street research shows a cluster of price target increases for Roivant Sciences, with several firms revisiting their models around revenue potential, profitability and valuation multiples.
Recent Insider Transactions Derivative • Feb 10President notifies of intention to sell stockMayukh Sukhatme intends to sell 339k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of February. If the sale is conducted around the recent share price of US$26.47, it would amount to US$9.0m. Mayukh now holds 18.84m shares directly in their own name. Company insiders have collectively sold US$293m more than they bought, via options and on-market transactions in the last 12 months.
Price Target Changed • Feb 08Price target increased by 7.7% to US$29.09Up from US$27.00, the current price target is an average from 11 analysts. New target price is 13% above last closing price of US$25.82. Stock is up 137% over the past year. The company is forecast to post a net loss per share of US$1.19 next year compared to a net loss per share of US$0.75 last year.
Reported Earnings • Feb 07Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: US$0.38 loss per share (further deteriorated from US$0.22 loss in 3Q 2025). Revenue: US$2.00m (down 78% from 3Q 2025). Net loss: US$265.9m (loss widened 69% from 3Q 2025). Revenue missed analyst estimates by 67%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings.
공시 • Feb 06Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Interstitial Lung DiseasePulmovant, and a Roivant company announced that it has completed enrollment in the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. Mosliciguat is a potential first-in-class, once-daily, inhaled sGC activator with a differentiated mechanism of action designed to deliver targeted pulmonary vasodilation with limited systemic side effects for the treatment of PH-ILD. Pulmovant completed enrollment of the PHocus clinical trial in under 12 months from first patient dosed, an impressive timeline in clinical development of treatments for PH-ILD. Pulmovaant remains on track to report PHocus topline data in the second half of calendar year 2026. The Phase 2 PHocus clinical study (NCT06635850) is a randomized, double-blind, placebo-controlled, global trial assessing the safety and efficacy of mosliciguat in approximately 120 adult participants with PH-ILD.Mosliciguat is also being evaluated in the Phase 2 PHactor clinical study (NCT07333183), an open-label trial evaluating the tolerability and safety of inhaled mosliciguat in combination with inhaled treprostinil in participants with PH-ILD. The Phase 2 PH focus clinical study (NCT0 6635850) is a randomized. double-blind, placebo- controlled, global trial evaluating the safety and efficacy of Mosliciguat in approximately120 adult participants with PH-ILD; Mosliciguat is also be evaluated in the Phase 2 PHact clinical study (NCT0733183), an open- label trial evaluating the tolerability and Safety of inhaled moslicigUat in combination with inhaled Treprostinil in Participants with PH-ILD. PulmOVant is a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases and is a Roivant company. Pulmovant's first investigational candidate, Mosliciguat, is designed to provide a novel, once- daily, inhaled treatment option for patients with pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD). Mosliciguat is an potential first-in-classsoluble guanylate cyclase activator with a differentiated mechanismof action currently being evaluated in the Phase 2PHocus clinical trial in under 12 years.
내러티브 업데이트 • Feb 06ROIV: 2026 Trial Results And IP Litigation Are Expected To Unlock UpsideNarrative Update Analysts have lifted their blended price target on Roivant Sciences by US$3, citing recent Street research that points to ongoing batoclimab Phase 3 trial progress, a clearer 2026 data timeline, and Roivant's position in the royalty dispute backdrop with Moderna. Analyst Commentary Street research on Roivant Sciences is generally constructive, with recent notes focusing on valuation support from batoclimab, the timing of key Phase 3 readouts, and the ongoing royalty dispute backdrop with Moderna.
공시 • Jan 24Roivant Sciences Ltd. to Report Q3, 2026 Results on Feb 06, 2026Roivant Sciences Ltd. announced that they will report Q3, 2026 results Pre-Market on Feb 06, 2026
내러티브 업데이트 • Jan 22ROIV: 2026 Trial Readouts And IP Litigation Are Expected To Drive UpsideNarrative Update: Roivant Sciences (ROIV) Analysts have modestly raised their average price target on Roivant Sciences to about $27, citing updated assumptions around batoclimab trial timelines into 2026 and Roivant's role in ongoing Moderna IP litigation as key factors behind the revised outlook. Analyst Commentary Recent research points to a mixed but generally constructive view on Roivant Sciences, with attention on batoclimab timing and the evolving relationship with Moderna as key inputs into valuation and execution risk.
Recent Insider Transactions Derivative • Jan 13President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of January. If the sale is conducted around the recent share price of US$21.92, it would amount to US$4.4m. Since March 2025, Eric's direct individual holding has increased from 883.70k shares to 1.33m. Company insiders have collectively sold US$290m more than they bought, via options and on-market transactions in the last 12 months.
내러티브 업데이트 • Jan 08ROIV: 2026 Clinical Readouts And LNP Litigation Are Expected To Drive UpsideAnalysts have lifted their price expectations for Roivant Sciences, with the blended fair value estimate moving from US$25.64 to about US$27.00 as they weigh updated Phase 3 timelines, a slightly lower discount rate, and higher assumed future P/E multiples, alongside perceived improvements in counter-party credit quality related to ongoing IP litigation. Analyst Commentary Recent Street research on Roivant Sciences reflects a mix of optimism around the pipeline and valuation support, alongside some caution on execution timing and external legal factors.
Price Target Changed • Jan 07Price target increased by 10% to US$27.00Up from US$24.55, the current price target is an average from 11 analysts. New target price is 23% above last closing price of US$21.96. Stock is up 99% over the past year. The company is forecast to post a net loss per share of US$1.16 next year compared to a net loss per share of US$0.75 last year.
Recent Insider Transactions • Dec 31Chief Financial Officer recently sold US$3.3m worth of stockOn the 23rd of December, Richard Pulik sold around 147k shares on-market at roughly US$22.39 per share. This transaction amounted to 73% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$38m. This was Richard's only on-market trade for the last 12 months.
내러티브 업데이트 • Dec 15ROIV: Late Stage Pipeline And LNP Litigation Will Drive Upside Into 2026Analysts have nudged their blended fair value estimate for Roivant Sciences higher, lifting the implied price target by about $1 to approximately $25.64. They are factoring in a richer future earnings multiple and growing confidence in the company’s late stage pipeline and ongoing litigation optionality, despite slightly softer margin and growth assumptions.
공시 • Dec 11Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth At 2025 Investor DayRoivant announced positive updates to timing guidance across four key programs: Brepocitinib NDA filing in dermatomyositis (DM) now expected in early calendar year 2026; commercial preparation underway with launch expected early in calendar year 2027; Brepocitinib Phase 3 trial in non-infectious uveitis (NIU) fully enrolled with topline data now expected in the second half of calendar year 2026; commercial preparations underway with launch expected early in fiscal year 2027; Bre pocitinib Phase 3 trials in non-infectious uVEitis (NIU) fully enroll with topline data now expects in the first half of calendar year 2026, and a proof-of-concept trial in cutaneous lupus erythematosus (CLE) Mosliciguat: Enrollment in the ongoing Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) remains on track; Pulmovant plans to report topline data in the second half of calendaryear 2026, previously expected in the second half of fiscal year 2026; previously expected Period 1 data in calendar year 2026 and topline data in calendar year 2027; All other clinical development timelines remain on track, including potentially registrational trials in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjogren's disease (SjD), and a proof-of- concept trial in cutaneous lupUS erythematosus ("CLE") Mosliciguat") Enrollment in the ongoing Phase2 trial of moslicigu at pulmonary hypertension associated with interstitial lupus erytheMatosus (CLE). Pulmovant also expects to imminently initiate a Phase 2 study (n=20) evaluating mosliciguat in combination with inhaled treprostinil in patients with PH-ILD Genevant. In the US Moderna litigation, a jury trial has been scheduled for March 2026. Awaiting court scheduling in the Pfizer/BioNTech litigation. Initial court hearings and rulings in the ex-US Moderna litigation expected in calendar year 2026.
Recent Insider Transactions Derivative • Dec 10President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of December. If the sale is conducted around the recent share price of US$20.85, it would amount to US$4.2m. Since December 2024, Eric's direct individual holding has increased from 438.01k shares to 1.17m. Company insiders have collectively sold US$153m more than they bought, via options and on-market transactions in the last 12 months.
내러티브 업데이트 • Nov 30ROIV: Positive Phase 3 Data Will Drive Shares Into 2026 And BeyondThe analyst price target for Roivant Sciences has increased from approximately $23.27 to $24.55. Analysts cite stronger revenue growth forecasts and recent positive clinical trial updates as factors driving an improved company outlook.
Recent Insider Transactions • Nov 19Insider recently sold US$38m worth of stockOn the 17th of November, Vivek Ramaswamy sold around 2m shares on-market at roughly US$20.46 per share. This transaction amounted to 3.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$110m more than they bought in the last 12 months.
내러티브 업데이트 • Nov 16ROIV: Upcoming Data From Phase 3 Trials Will Drive Shares HigherAnalysts have raised their fair value estimate for Roivant Sciences from $20.86 to $23.27 per share. They cite strong Phase 3 trial results, continued clinical progress, and anticipated upcoming catalysts as key factors behind the updated price target.
Reported Earnings • Nov 12Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2026 results: US$0.17 loss per share (improved from US$0.25 loss in 2Q 2025). Revenue: US$1.57m (down 65% from 2Q 2025). Net loss: US$113.5m (loss narrowed 39% from 2Q 2025). Revenue missed analyst estimates by 75%. Earnings per share (EPS) exceeded analyst estimates by 49%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions Derivative • Nov 09President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of November. If the sale is conducted around the recent share price of US$20.22, it would amount to US$4.0m. Since December 2024, Eric's direct individual holding has increased from 438.01k shares to 1.17m. Company insiders have collectively sold US$113m more than they bought, via options and on-market transactions in the last 12 months.
내러티브 업데이트 • Oct 31ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term OutlookThe analyst price target for Roivant Sciences has been increased by approximately $0.82 to $20.86 per share. Analysts cite strong Phase 3 trial results and a positive outlook for brepocitinib as key drivers of their upward revisions.
공시 • Oct 28Roivant Sciences Ltd. to Report Q2, 2026 Results on Nov 10, 2025Roivant Sciences Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025
내러티브 업데이트 • Oct 17Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks RemainAnalysts have recently increased their price targets for Roivant Sciences. The consensus has moved higher by several dollars per share as positive Phase 3 results for brepocitinib and progress in litigation bolster confidence in the company's outlook.
Recent Insider Transactions Derivative • Oct 07President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 171k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of October. If the sale is conducted around the recent share price of US$16.34, it would amount to US$2.8m. Since December 2024, Eric's direct individual holding has increased from 438.01k shares to 1.17m. Company insiders have collectively sold US$108m more than they bought, via options and on-market transactions in the last 12 months.
내러티브 업데이트 • Oct 03Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks RemainThe analyst consensus price target for Roivant Sciences has increased from $18.30 to $20.05. Analysts cite strong Phase 3 dermatomyositis data and anticipated commercial potential as key drivers for the upward revision.
Recent Insider Transactions • Sep 25President & CEO of Immunovant recently sold US$17m worth of stockOn the 23rd of September, Eric Venker sold around 1m shares on-market at roughly US$14.90 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$22m. This was Eric's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Sep 21President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 684k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of September. If the sale is conducted around the recent share price of US$14.95, it would amount to US$10m. Since December 2024, Eric's direct individual holding has increased from 438.01k shares to 1.31m. Company insiders have collectively sold US$155m more than they bought, via options and on-market transactions in the last 12 months.
Price Target Changed • Sep 18Price target increased by 16% to US$19.64Up from US$17.00, the current price target is an average from 11 analysts. New target price is 30% above last closing price of US$15.09. Stock is up 27% over the past year. The company is forecast to post a net loss per share of US$1.35 next year compared to a net loss per share of US$0.75 last year.
내러티브 업데이트 • Sep 18Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks RemainAnalysts have raised Roivant Sciences’ price target from $17.00 to $18.30, citing bullish expectations for favorable Phase 3 brepocitinib data in dermatomyositis as a key catalyst and reflecting increased optimism around near-term pipeline milestones. Analyst Commentary Bullish analysts expect favorable risk/reward ahead of brepocitinib Phase 3 data in dermatomyositis, with key results anticipated in September.
공시 • Sep 17Roivant and Priovant Announce Positive Phase 3 Valor Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in DermatomyositisRoivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM). On the primary endpoint, brepocitinib 30 mg achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo (p=0.0006), even with nearly twice as many patients coming off background steroid on brepocitinib30 mg compared to placebo. More than two thirds of brepocitinib 300 mg patients experienced at least a moderate response (TIS40), and nearly half experienced a major response (TIS60). Consistent dose response was seen between 30 mg and 15 mg dose arms, establishing 30 mg dose as optimal in this setting. Safety profile was consistent with previous brepocitinib and NDA filing is planned for calendar 1H 2026. The observed brepocitinib 25 mg safety profile was consistent with previous bre p<0.0006. The observed brepoc itinib 30 mg safety profile was consistent with previously brepocitinib clinical trials. Adverse events of special interest (AESIs), which included malignancy, cardiovascular events, and thromboembolic events, did not occur with greater frequency in the brepocitinib 50 mg arm than the placebo arm. Priovant plans to file an NDA for brepocit in dermatomyositis in the first half of 2026.
공시 • Sep 15ProofPilot, Inc. acquired Lokavant, Inc.ProofPilot, Inc. acquired Lokavant, Inc. on September 15, 2025. ProofPilot, Inc. completed the acquisition of Lokavant, Inc. on September 15, 2025.
Recent Insider Transactions • Sep 08Insider recently sold US$22m worth of stockOn the 5th of September, Vivek Ramaswamy sold around 2m shares on-market at roughly US$12.65 per share. This transaction amounted to 3.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$106m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Aug 21President & CEO of Immunovant notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of August. If the sale is conducted around the recent share price of US$11.72, it would amount to US$1.2m. Since September 2024, Eric's direct individual holding has increased from 266.07k shares to 1.31m. Company insiders have collectively sold US$131m more than they bought, via options and on-market transactions in the last 12 months.
Major Estimate Revision • Aug 18Consensus revenue estimates fall by 17%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$28.5m to US$23.7m. Forecast losses increased from -US$1.29 to -US$1.36 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$17.11. Share price rose 6.1% to US$11.85 over the past week.
Reported Earnings • Aug 12First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: US$0.33 loss per share (down from US$0.008 profit in 1Q 2025). Revenue: US$2.17m (down 73% from 1Q 2025). Net loss: US$223.4m (down US$229.6m from profit in 1Q 2025). Revenue missed analyst estimates by 69%. Earnings per share (EPS) also missed analyst estimates by 26%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 41% per year.
공시 • Aug 12Roivant Sciences Ltd. (NasdaqGS:ROIV) announces an Equity Buyback for $500 million worth of its shares.Roivant Sciences Ltd. (NasdaqGS:ROIV) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its common shares.
공시 • Jul 30Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2025Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2025. Location: royal lancaster london hotel, lancaster terrace, london w2 2ty, united kingdom, United Kingdom
공시 • Jul 29Roivant Sciences Ltd. to Report Q1, 2026 Results on Aug 11, 2025Roivant Sciences Ltd. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Aug 11, 2025
Recent Insider Transactions Derivative • Jul 22President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of July. If the sale is conducted around the recent share price of US$11.52, it would amount to US$1.2m. Since September 2024, Eric's direct individual holding has increased from 266.07k shares to 1.31m. Company insiders have collectively sold US$131m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Jun 08Insider recently sold US$8.5m worth of stockOn the 6th of June, Vivek Ramaswamy sold around 748k shares on-market at roughly US$11.30 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$10m. Insiders have been net sellers, collectively disposing of US$71m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Jun 03President & COO notifies of intention to sell stockEric Venker intends to sell 434k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of June. If the sale is conducted around the recent share price of US$11.07, it would amount to US$4.8m. Since June 2024, Eric's direct individual holding has increased from 239.53k shares to 853.40k. Company insiders have collectively sold US$102m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • May 30Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: US$0.75 loss per share (down from US$5.55 profit in FY 2024). Revenue: US$29.1m (down 77% from FY 2024). Net loss: US$545.0m (down 113% from profit in FY 2024). Revenue missed analyst estimates by 79%. Earnings per share (EPS) exceeded analyst estimates by 27%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions Derivative • May 21President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of May. If the sale is conducted around the recent share price of US$10.95, it would amount to US$1.1m. Since June 2024, Eric's direct individual holding has increased from 239.53k shares to 892.55k. Company insiders have collectively sold US$102m more than they bought, via options and on-market transactions in the last 12 months.
공시 • May 16Roivant Sciences Ltd. to Report Q4, 2025 Results on May 29, 2025Roivant Sciences Ltd. announced that they will report Q4, 2025 results on May 29, 2025
Recent Insider Transactions • May 11Insider recently sold US$10m worth of stockOn the 7th of May, Vivek Ramaswamy sold around 899k shares on-market at roughly US$11.27 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$62m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Apr 23President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of April. If the sale is conducted around the recent share price of US$10.22, it would amount to US$1.0m. Since June 2024, Eric's direct individual holding has increased from 239.53k shares to 883.70k. Company insiders have collectively sold US$91m more than they bought, via options and on-market transactions in the last 12 months.
Seeking Alpha • Apr 23Roivant Sciences: Primed For Growth With A De-Risked PipelineSummary Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs. Current market valuations significantly undervalue Roivant's potential peak sales, suggesting substantial upside potential given its strong cash position and de-risked late-stage pipeline. Read the full article on Seeking Alpha
Recent Insider Transactions Derivative • Mar 21President & COO notifies of intention to sell stockEric Venker intends to sell 650k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of March. If the sale is conducted around the recent share price of US$10.95, it would amount to US$7.1m. Since June 2024, Eric's direct individual holding has increased from 239.53k shares to 622.55k. Company insiders have collectively sold US$93m more than they bought, via options and on-market transactions in the last 12 months.
공시 • Feb 22Roivant Sciences Ltd. Announces Stepping Down of Rakhi Kumar as Principal Accounting OfficerRoivant Sciences Ltd. announced stepping down of Rakhi Kumar as Principal Accounting Officer, effective February 20, 2025.
Recent Insider Transactions • Feb 20Chief Accounting Officer recently sold US$417k worth of stockOn the 13th of February, Rakhi Kumar sold around 40k shares on-market at roughly US$10.43 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$52m more than they bought in the last 12 months.
Major Estimate Revision • Feb 17Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from US$119.5m to US$141.3m. Forecast losses expected to reduce from -US$0.736 to -US$0.329 per share. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target broadly unchanged at US$16.00. Share price fell 2.1% to US$10.56 over the past week.
Recent Insider Transactions Derivative • Feb 13President & COO notifies of intention to sell stockEric Venker intends to sell 600k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of February. If the sale is conducted around the recent share price of US$10.50, it would amount to US$6.3m. Since March 2024, Eric's direct individual holding has increased from 204.81k shares to 449.12k. Company insiders have collectively sold US$88m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Feb 10Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.22 loss per share (down from US$6.37 profit in 3Q 2024). Revenue: US$9.02m (down 76% from 3Q 2024). Net loss: US$157.6m (down 103% from profit in 3Q 2024). Revenue exceeded analyst estimates by 90%. Earnings per share (EPS) also surpassed analyst estimates by 178%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Seeking Alpha • Feb 05Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)Summary Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results. Company maintains strong financials with $5.4B in cash/investments and 6-year runway at current burn rate of $76M monthly. I am downgrading to "hold" given the unclear path to profitability and challenges in differentiating clinical assets, though I still see value in a barbell portfolio. Read the full article on Seeking Alpha
공시 • Jan 30Roivant Sciences Ltd. to Report Q3, 2025 Results on Feb 10, 2025Roivant Sciences Ltd. announced that they will report Q3, 2025 results on Feb 10, 2025
새로운 내러티브 • Jan 26Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.
Recent Insider Transactions Derivative • Jan 22President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of January. If the sale is conducted around the recent share price of US$11.28, it would amount to US$1.1m. Since March 2024, Eric's direct individual holding has increased from 204.81k shares to 438.01k. Company insiders have collectively sold US$88m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Dec 19President notifies of intention to sell stockMayukh Sukhatme intends to sell 413k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of December. If the sale is conducted around the recent share price of US$12.05, it would amount to US$5.0m. Since December 2023, Mayukh's direct individual holding has decreased from 3.29m shares to 0. Company insiders have collectively sold US$109m more than they bought, via options and on-market transactions in the last 12 months.
Seeking Alpha • Dec 04Roivant Sciences: A Biotech Growth Play With Major AmbitionsSummary Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat position Roivant for significant clinical and commercial milestones by 2025. Strategic divestitures, like Dermavant's sale to Organon for $1.2 billion, support shareholder value through share buybacks and bolster financial stability. ROIV has legal risks from ongoing LNP technology lawsuits, but favorable outcomes could significantly improve its long-term outlook as well. Despite its clinical, legal, and cash burn risks, Roivant's diversified late-stage pipeline and robust financials promise significant growth potential. Read the full article on Seeking Alpha
공시 • Dec 03Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisKinevant Sciences announced its Phase 2 study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. The Phase 2 RESOLVE-Lung study (NCT05314517) evaluated the efficacy and safety of namilumab, an investigational anti-GM-CSF monoclonal antibody administered once-monthly as a subcutaneous injection, in participants with chronic active pulmonary sarcoidosis. Primary Endpoint Details: Namilumab failed to meet the primary endpoint of proportion of subjects with a Rescue Event during the double-blind period. Secondary Endpoints Details: Secondary efficacy endpoints, including change in percent predicted forced vital capacity, corticosteroid tapering success, and change in the patient reported King’s Sarcoidosis Questionnaire failed to show a treatment benefit consistent with the primary endpoint. Safety Details: The safety profile of namilumab in RESOLVE-Lung remains similar to previous studies. With these results, Kinevant will be discontinuing further development of namilumab for the treatment of sarcoidosis. Kinevant is committed to publishing the results of RESOLVE-Lung to inform future sarcoidosis research. The RESOLVE-Lung study is a Phase 2 randomized, double-blind, placebo-controlled study of namilumab for the treatment of pulmonary sarcoidosis at sites in the U.S. and Europe. The study enrolled 107 patients with pulmonary sarcoidosis considered to have chronic, active disease not well-controlled despite available therapeutic options. Patients in the study received a once-monthly subcutaneous injection of namilumab or placebo (following the initial dosing period) for approximately six months. All patients who complete the 26-week double-blind treatment period were eligible to participate in a 28-week open-label extension treatment period on namilumab. The primary endpoint of this study was proportion of subjects with a Rescue Event during the double-blind period. Rescue Event was defined as clinically significant worsening of a subject’s sarcoidosis requiring treatment, failure to adhere to the protocol defined OCS taper, or premature discontinuation from the study associated with lack of benefit during the double-blind treatment period. Study eligibility did not require subjects to be on high dose corticosteroids. If subjects were on >5mg/day of oral corticosteroid (OCS) at baseline, they were required to taper down to 5mg/day 8-10 weeks after randomization. If patients were on an immunosuppressive therapy (IST), they were required to stop the IST at randomization. Notably, all subjects enrolled had evidence of active pulmonary sarcoidosis disease, defined as a positive HRCT scan, significant lung inflammation on PET, and moderate to severe self-reported breathlessness. Pulmonary sarcoidosis is a lung disease characterized by the presence of granulomas (clumps of immune cells) of unknown etiology that can cause breathlessness, fatigue, and pain. The resulting inflammation, if not effectively treated, can result in lung tissue scarring (fibrosis), lung dysfunction, and eventually lung failure. Approximately 50% of diagnosed patients require chronic therapy to treat symptoms and prevent progression. Oral steroids (e.g., prednisone) and off-label immunosuppressive therapies (e.g., methotrexate) are first- and second-line therapies respectively for sarcoidosis; however, these therapeutic options are often not effective or can be accompanied by serious side effects. Approximately 200,000 people in the U.S. (and more than 1 million worldwide) are estimated to have sarcoidosis, an immune-mediated inflammatory disease that can affect any organ in the body, with about 90% of cases involving the lung. Granulocyte macrophage colony stimulating factor (GM-CSF) is a pro-inflammatory cytokine over-expressed in several inflammatory diseases, including sarcoidosis. GM-CSF mediated pro-inflammatory signaling is thought to play a central role in recruitment of macrophages and monocytes to the lung and to trigger a granulomatous response, including the fusion of macrophages into multinucleated giant cells. Namilumab is an anti-GM-CSF monoclonal antibody formulated to be administered once-monthly as a subcutaneous injection being investigated for the treatment of pulmonary sarcoidosis.
Recent Insider Transactions Derivative • Nov 21President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of November. If the sale is conducted around the recent share price of US$11.32, it would amount to US$1.1m. Since December 2023, Eric's direct individual holding has increased from 162.38k shares to 274.92k. Company insiders have collectively sold US$109m more than they bought, via options and on-market transactions in the last 12 months.
Major Estimate Revision • Nov 19Consensus revenue estimates decrease by 36%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$194.0m to US$125.0m. EPS estimate unchanged at -US$0.727 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$16.94 to US$16.21. Share price fell 5.5% to US$11.16 over the past week.
New Risk • Nov 14New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 1,958% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 53% per year for the foreseeable future. High level of non-cash earnings (1,958% accrual ratio). Minor Risk Significant insider selling over the past 3 months (US$52m sold).
Reported Earnings • Nov 13Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: US$0.25 loss per share (improved from US$0.40 loss in 2Q 2024). Revenue: US$4.48m (down 88% from 2Q 2024). Net loss: US$187.1m (loss narrowed 39% from 2Q 2024). Revenue missed analyst estimates by 43%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
공시 • Oct 30Roivant Sciences Ltd. to Report Q2, 2025 Results on Nov 12, 2024Roivant Sciences Ltd. announced that they will report Q2, 2025 results on Nov 12, 2024
공시 • Oct 28Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others.Organon & Co. (NYSE:OGN) entered into an Agreement and Plan of Merger to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion on September 17, 2024. A cash consideration, Organon to acquire Dermavant for aggregate consideration of up to approximately $1.2 billion, comprising (i) a payment of $175 million payable at the closing of the Merger, subject to certain adjustments, (ii) a $75 million milestone payment payable upon FDA approval of VTAMA product for the treatment of atopic dermatitis and (iii) up to $950 million in additional milestone payments payable upon achievement of certain tiered net sales amounts with respect to the Product, each less than or equal to $1 billion. Additionally, Organon has agreed to make tiered royalty payments of (x) low-to-mid single digit percentages with respect to annual net sales of the Product up to $1 billion and (y) 30% with respect to annual net sales of the Product above $1 billion. Upon closing of the transaction, as part of the purchase price consideration, Organon would assume Dermavant liabilities with an approximate value of $286 million reported by Roivant as of June 30, 2024, which would be subject to fair value accounting by Organon. Dermavant owns the rights to VTAMA cream globally excluding China and has out licensed Japan rights. Pursuant to the terms of the Merger Agreement, Dermavant continuing as the surviving company and a wholly owned subsidiary of Organon. The boards of directors of the Company and of Dermavant each approved the entry into the Merger Agreement and the consummation of the Merger. Concurrently with the entry into the Merger Agreement, the Merger Agreement and the Merger were approved by written consent of shareholders constituting at least 75% of the aggregate voting rights of Dermavant’s issued and outstanding common and preference shares. Completion of the transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to be modestly dilutive to Adjusted EBITDA in 2025, turning accretive in 2026. Organon expects net leverage to be elevated above 4.0x as a result of the transaction. The transaction is not expected to result in a revision to Organon’s capital allocation priorities. Company and Organon has the right to terminate the Merger Agreement and abandon the Merger in the event that the Merger has not been consummated by January 5, 2025 due to failure to satisfy certain antitrust-related conditions. Closing of the transaction is currently expected to take place in the fourth quarter of 2024. Damien Zoubek, Jenny Hochenberg and Tomas Rua, Jeff Jay, Lori Goodman, Steven Matays, Meghan Rissmiller and Rod Carlton, Charles Ramsey, Christine Lyon and Brock Dahl and Stephanie Brown-Cripps of Freshfields Bruckhaus Deringer LLP acted as legal advisor for Roivant Sciences Ltd and Dermavant Sciences Ltd. Goldman Sachs & Co. LLC acted as financial advisor for Roivant Sciences Ltd. Catherine Dargan and Patrick Manchester of Covington & Burling LLP acted as legal advisor for Organon & Co. Deloitte & Touche LLP acted as accountant to Roivant Sciences Ltd. Conyers Dill & Pearman LLP acted as Bermuda legal advisor for Roivant Sciences Ltd. Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others on October 28, 2024.
Recent Insider Transactions Derivative • Oct 23President & COO notifies of intention to sell stockEric Venker intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of October. If the sale is conducted around the recent share price of US$11.65, it would amount to US$1.2m. Since December 2023, Eric's direct individual holding has increased from 162.38k shares to 266.07k. Company insiders have collectively sold US$108m more than they bought, via options and on-market transactions in the last 12 months.
Seeking Alpha • Oct 22Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring VolatilitySummary Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant’s batoclimab in Phase 3 trials and namilumab in a Phase 2 trial, though drug candidate performance remains a critical risk factor. Litigation against Moderna and Pfizer, coupled with Techbio advancements, could drive future valuation. Read the full article on Seeking Alpha
Recent Insider Transactions Derivative • Oct 03Independent Director notifies of intention to sell stockDaniel Gold intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 24th of September. If the sale is conducted around the recent share price of US$11.63, it would amount to US$18m. Since March 2024, Daniel's direct individual holding has decreased from 9.91m shares to 6.43m. Company insiders have collectively sold US$116m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Sep 26CEO & Director recently sold US$5.1m worth of stockOn the 23rd of September, Matthew Gline sold around 433k shares on-market at roughly US$11.79 per share. This transaction amounted to 2.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Matthew's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Sep 25CEO & Director notifies of intention to sell stockMatthew Gline intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of September. If the sale is conducted around the recent share price of US$11.79, it would amount to US$23m. For the year to March 2021, Matthew's total compensation was 98% salary and 2% non-salary. Since September 2023, Matthew's direct individual holding has increased from 645.38k shares to 931.79k. Company insiders have collectively sold US$55m more than they bought, via options and on-market transactions in the last 12 months.
공시 • Sep 18Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion.Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) from and others for approximately $1.2 billion on September 18, 2024. A cash consideration will be paid by Organon & Co. Organon has agreed to acquire Dermavant for aggregate consideration of up to approximately $1.2 billion, with an upfront payment of $175 million and a $75 million milestone payment upon regulatory approval in AD, as well as payments of up to $950 million for the achievements of certain commercial milestones. Upon closing of the transaction, as part of the purchase price consideration, Organon would assume Dermavant liabilities with an approximate value of $286 million reported by Roivant as of June 30, 2024, which would be subject to fair value accounting by Organon. In addition, Organon will pay Dermavant shareholders tiered royalties on net sales. Dermavant owns the rights to VTAMA cream globally excluding China and has out licensed Japan rights. Completion of the transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Closing of the transaction is currently expected to take place in the fourth quarter of 2024. The transaction is expected to be modestly dilutive to Adjusted EBITDA in 2025, turning accretive in 2026. Organon expects net leverage to be elevated above 4.0x as a result of the transaction. The transaction is not expected to result in a revision to Organon’s capital allocation priorities. Freshfields Bruckhaus Deringer LLP acted as legal advisor for Roivant Sciences Ltd. Goldman Sachs & Co. LLC acted as financial advisor for Roivant Sciences Ltd. Covington & Burling LLP acted as legal advisor for Organon & Co.
Seeking Alpha • Aug 22Roivant Sciences: Inherently Risky Business Model, But Track Record ImpressesSummary Roivant Sciences stock has risen significantly since my initial coverage in 2022, with a positive market response to fiscal year 2025 Q1 earnings. Roivant operates by creating "nimble subsidiaries to develop and commercialize medicines", with a focus on unearthing strong drug candidates for lucrative exits. Key drugs in Roivant's pipeline include VTAMA, Batoclimab, and Breproctinib, each facing competition and uncertainties in their respective markets. Roivant was founded by a venture capitalist and is currently run by an ex-Goldman Sachs banker - after securing the $7bn exit of Televant to Roche last year, the company is cash rish. Across the next 12 months, most of Roivant's key assets will read out key data in key indications - we are at the beginning of a "make-or-break" year for the company that ought to create significant price volatility. Read the full article on Seeking Alpha
Major Estimate Revision • Aug 16Consensus revenue estimates increase by 18%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$147.7m to US$174.2m. EPS estimate unchanged from -US$0.70 at last update. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target of US$16.67 unchanged from last update. Share price rose 4.2% to US$11.31 over the past week.
New Risk • Aug 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 1,252% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 60% per year for the foreseeable future. High level of non-cash earnings (1,252% accrual ratio).
Reported Earnings • Aug 09First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.13 (up from US$0.38 loss in 1Q 2024). Revenue: US$55.1m (up 155% from 1Q 2024). Net income: US$95.3m (up US$387.1m from 1Q 2024). Revenue exceeded analyst estimates by 86%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
공시 • Jul 29Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2024Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2024. Location: royal lancaster london hotel, lancaster terrace, london w2 2ty, united kingdom on, london United States
